Halozyme: Takeda receives FDA approval of HYQVIA co-formulated with ENHANZE

Halozyme Therapeutics (HALO) announced that Takeda (TAK) received U.S. FDA approval for HYQVIA co-formulated with Halozyme’s ENHANZE drug delivery technology for the treatment of chronic inflammatory demyelinating polyneuropathy as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults. HYQVIA was first granted FDA approval in 2014 for the treatment of primary immunodeficiency in adults, which has since been expanded to include children 2-16 years old